Long-term survival of a patient with locally advanced hilar cholangiocarcinoma (Klatskin tumor): a case report and review on high level evidence

  • Jalal Vahedian Department of Surgery, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
  • Mohammad Reza Babaei Department of Interventional Radiology, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
  • Ali Zare Mehrjardi Department of Pathology, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
  • Ali Almasi Department of Surgery, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
  • Seyyed Amir Yasin Ahmadi Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.
  • Omid Hadizadeh Department of Surgery, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
Keywords: Survival, Stents, Cholangiocarcinoma,

Abstract


Cholangiocarcinoma, malignant tumor of epithelial cells of bile ducts has poor overall survival and prognosis. We report a case of non-resectable cholangiocarcinoma with a 57-month survival after incomplete R2 surgical margin resection of the tumor. A 52-year old man with generalized itching, jaundice, brownish urine, mild abdominal pain and weight loss of 8 kg in last two months presented. Imaging and surgical workups showed hilar cholangiocarcinoma (Klatskin tumor). Along with incomplete R2 margin resection we performed stent embedding and post-operative adjuvant chemotherapy. Based on current literature data there is no superiority of adjuvant chemotherapy after complete R0 resection compared to incomplete R2 resection. However, it seems that partial resection along with stent embedding and applied adjuvant chemotherapy in cases of locally advanced non-resectable cholangiocarcinoma may increase survival rate.

References

Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA: A cancer journal for clinicians. CA: A Cancer Journal for Clinicians 1997;47(1):5-27. doi: 10.3322/canjclin.47.1.5

Shaib Y, El-Serag H. The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease 2004;24(02):115-125. doi: 10.1055/s-2004-828889

Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, Dugan JM. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Annals of Surgery 2000;232(2):166-174. doi: 10.1097/00000658-200008000-00003

Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. Journal of Gastrointestinal Surgery 2007;11(11):1488-1497. doi: 10.1007/s11605-007-0282-0

Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surgery 2014;149(6):565. doi: 10.1001/jamasurg.2013.5137

Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. Journal of Hepatology 2002;37(6):806-813. doi: 10.1016/s0168-8278(02)00297-0

Olnes MJ, Erlich R. A Review and Update on Cholangiocarcinoma. Oncology 2004;66(3):167-179. doi: 10.1159/000077991

Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75(S1):171-90.

Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. The Lancet 2005;366(9493):1303-1314. doi: 10.1016/s0140-6736(05)67530-7

Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54(1):173-184. doi: 10.1002/hep.24351

Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. Journal of Hepatology 2012;57(1):69-76. doi: 10.1016/j.jhep.2012.02.022

Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. The Lancet 2013;382(9904):1587-1599. doi: 10.1016/s0140-6736(13)60096-3

Ren H, Yu T, Liu C, Li Y. Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis. Cancer Causes and Control 2011;22(6):837-847. doi: 10.1007/s10552-011-9754-3

Blechacz B, Gores GJ. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48(1):308-321. doi: 10.1002/hep.22310

DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Schulick RD. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of Surgery 2007;245(5):755-762. doi: 10.1097/01.sla.0000251366.62632.d3

Kahaleh M, Mishra R, Shami VM, Northup PG, Berg CL, Bashlor P, Yeaton P. Unresectable Cholangiocarcinoma: Comparison of Survival in Biliary Stenting Alone Versus Stenting With Photodynamic Therapy. Clinical Gastroenterology and Hepatology 2008;6(3):290-297. doi: 10.1016/j.cgh.2007.12.004

Mihalache F, Tantau M, Diaconu B, Acalovschi M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. Journal of Gastrointestinal & Liver Diseases. 2010;19(3).

Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factors. Asian Journal of Surgery 2017;40(2):129-138. doi: 10.1016/j.asjsur.2015.07.002

Wellner UF, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surgery Today 2017;47(3):271-279. doi: 10.1007/s00595-016-1362-0

Li M, Bi X, Li Z, Huang Z, Han Y, Zhao J, Cai J. Impaction of surgical margin status on the survival outcome after surgical resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Journal of Surgical Research 2016;203(1):163-173. doi: 10.1016/j.jss.2016.02.012

Tang H, Lu W, Li B, Meng X, Dong J. Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma: A meta-analysis. Medicine 2016;95(35):4621. doi: 10.1097/md.0000000000004621

Bird NTE, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. British Journal of Surgery 2018;105(11):1408-1416. doi: 10.1002/bjs.10921

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Sueda T. Gemcitabine-Based Adjuvant Chemotherapy Improves Survival After Aggressive Surgery for Hilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery 2009;13(8):1470-1479. doi: 10.1007/s11605-009-0900-0

Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz J, Blumgart LH. Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma. Annals of Surgery 2001;234(4):507-519. doi: 10.1097/00000658-200110000-00010

Kang MJ, Jang J, Chang J, Shin YC, Lee D, Kim HB, Kim S. Actual Long-Term Survival Outcome of 403 Consecutive Patients with Hilar Cholangiocarcinoma. World Journal of Surgery 2016;40(10):2451-2459. doi: 10.1007/s00268-016-3551-9

Published
2019/06/14
Section
Short Report